1. Philip J. Barter, et al. Circulation 2011;124:555-562

2. Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part I Philip J. Barter, et al. Circulation 2011;124:555-562

3. Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part II Philip J. Barter, et al. Circulation 2011;124:555-562

4. Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A1c, Serum Insulin,HOMA-IR, and HDL Cholesterol for the Subgroup of Diabetic Subjects Philip J. Barter, et al. Circulation 2011;124:555-562

5. Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - I Philip J. Barter, et al. Circulation 2011;124:555-562

6. Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - II Philip J. Barter, et al. Circulation 2011;124:555-562

7. Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A1c, Serum Insulin, HOMA-IR, and HDL Cholesterol for the Subgroup of Nondiabetic Subjects Philip J. Barter, et al. Circulation 2011;124:555-562

8. CLINICAL PERSPECTIVE Philip J. Barter, et al. Circulation 2011;124:555-562